Capricor Therapeutics (NASDAQ:CAPR) Shares Down 3.3% - Time to Sell?

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) shares were down 3.3% during mid-day trading on Monday . The stock traded as low as $21.02 and last traded at $21.06. Approximately 171,310 shares were traded during trading, a decline of 85% from the average daily volume of 1,145,589 shares. The stock had previously closed at $21.78.

Analysts Set New Price Targets

A number of brokerages have commented on CAPR. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 price target on shares of Capricor Therapeutics in a research note on Friday, September 20th. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an "overweight" rating and a $35.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Oppenheimer restated an "outperform" rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Finally, Maxim Group upped their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, Capricor Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $24.67.

Capricor Therapeutics Price Performance

The company's fifty day simple moving average is $10.76 and its 200 day simple moving average is $7.03.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). The company had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. On average, sell-side analysts predict that Capricor Therapeutics Inc will post -1.17 earnings per share for the current fiscal year.

Insider Activity

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the company's stock in a transaction dated Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 12.00% of the stock is currently owned by company insiders.

Institutional Trading of Capricor Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock valued at $9,274,000 after purchasing an additional 200,499 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock valued at $656,000 after buying an additional 84,350 shares during the last quarter. Marshall Wace LLP bought a new stake in Capricor Therapeutics in the 2nd quarter worth about $426,000. Rhumbline Advisers bought a new stake in Capricor Therapeutics in the 2nd quarter worth about $147,000. Finally, BNP Paribas Financial Markets purchased a new position in Capricor Therapeutics in the 1st quarter worth about $40,000. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.